Novo Nordisk's plant in Kalundborg, Denmark, the company's largest, has been pumping out products for nearly 45 years. When Novo needs a new product, it upgrades some portion of the plant and starts anew. That is what it is doing again.
Sanofi is rejigging its commercial operations, with two new executive vice presidents stepping up to the plate to replace the retiring global operations President Hanspeter Spek.
Yesterday Merck's top executives spent a considerable amount of time trying to reassure analysts that the Big Pharma company is actively engaged in the hunt for new drugs needed to beef up a weak pipeline.
Jockeying for a leading position in the high-stakes race to develop a new generation of blockbuster diabetes drugs, Merck is hitching a ride with Pfizer's late-stage SGLT2 candidate, ertugliflozin (PF-04971729).
Bristol-Myers Squibb's first-quarter earnings dropped 44%, on a 27% decline in sales. Fortunately, the $3.83 billion revenue line was only slightly worse than analysts expected, given generic competition for blockbuster heart drugs Avapro and Plavix.
Sanofi is expanding its infrastructure in Africa to take advantage of the growing market there. The emerging market is strategic enough that it drew Sanofi CEO Christopher A. Viehbacher to Morocco Thursday for the opening of a new logistics center.
The ruling not only opens GSK to the Humana suit, which applies to its Medicare Advantage plans, but also to potential lawsuits from other insurers.
Eli Lilly has made a huge bet on insulin to help it maneuver past patent losses for drugs like antidepressant Cymbalta which falls off this year. It has four new products in development, including one that could give Sanofi's Lantus a run for it money.
Eli Lilly has a slate of insulin products under development that it hopes will rejuvenate its fortunes. But it also gets 15% of its revenues from existing insulin products, which may come under price pressures as biosimilars hit the market.
Johnson & Johnson's new diabetes drug Invokana, previously known as canagliflozin, is the first FDA-approved treatment in a new class. That's something of a double-edged sword. It offers the promise of a novel approach to diabetes treatment, but because it's new, doctors may be in wait-and-see mode for awhile.